Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis

Company Overview

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins. Its development programs have included olverembatinib, a tyrosine kinase inhibitor for certain forms of chronic myeloid leukemia, as well as investigational candidates such as lisaftoclax (APG-2575), APG-115 and APG-1387. Olverembatinib has received approval in China for specified patients with chronic myeloid leukemia.

Founded in 2012, Ascentage Pharma conducts research and clinical development activities in China and internationally, with the objective of advancing therapies for cancers and other conditions with significant unmet medical needs. The company was founded by Dajun Yang, who has served as its chairman and chief executive officer.

Key Stats

• Today's Range: $15.58 to $15.71
• 50-Day Range: $15.06 to $20.40
• 52-Week Range: $15.02 to $40.47
• Volume: 1,460 shs
• Average Volume: 6,291 shs
• Market Capitalization: $1.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.43
• Consensus Rating: Buy

Ascentage Pharma Group International Stock Analysis - MarketRank™

Ascentage Pharma Group International scored higher than 63% of companies evaluated by MarketBeat, and ranked 283rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Buy

Consensus Rating

Ascentage Pharma Group International has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 2 strong buy ratings, 8 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Ascentage Pharma Group International has a consensus price target of $46.43, representing about 198.7% upside from its current price of $15.55.

Amount of Analyst Coverage

Ascentage Pharma Group International has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ascentage Pharma Group International are expected to grow in the coming year, from ($2.42) to $0.02 per share.

Price to Book Value per Share Ratio

Ascentage Pharma Group International has a P/B Ratio of 7.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Ascentage Pharma Group International has been sold short.

Short Interest Ratio / Days to Cover

Ascentage Pharma Group International has a short interest ratio ("days to cover") of 1.84, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ascentage Pharma Group International has recently increased by 7.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ascentage Pharma Group International does not currently pay a dividend.

Dividend Growth

Ascentage Pharma Group International does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: -0.35

News Sentiment

Ascentage Pharma Group International has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ascentage Pharma Group International this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for AAPG on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Ascentage Pharma Group International to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ascentage Pharma Group International insiders have not sold or bought any company stock.

Percentage Held by Institutions

Ascentage Pharma Group International has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/19/2026
• Today: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AAPG
• Previous Symbol: NASDAQ:AAPG
• CIK: 2023311
• Web: www.ascentage.com
• Phone: 86 512 8555 7777
• Fax: N/A
• Employees: 767
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Ascentage Pharma Group International: $46.43
• High Price Target: $51.00
• Low Price Target: $40.00
• Potential Upside/Downside: +198.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.09
• Current Ratio: 1.22
• Quick Ratio: 1.18

Sales & Book Value

• Annual Sales: $82.10 million
• Price / Sales: 17.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.04 per share
• Price / Book: 7.62

Miscellaneous

• Outstanding Shares: 93,400,000
• Free Float: N/A
• Market Cap: $1.45 billion
• Optionable: N/A
• Beta: 0.08